Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R J Griffiths

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Immunity|March 11, 1999
Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null miceT Y Nakagawa, W H Brissette, P D Lira, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|May 1, 1997
Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal modelsT J Carty, F J Sweeney, R J Griffiths, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 17, 1998
The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543H J Showell, M J Conklyn, R Alpert, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Immunity|March 11, 1999
Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null miceT Y Nakagawa, W H Brissette, P D Lira, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|May 1, 1997
Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal modelsT J Carty, F J Sweeney, R J Griffiths, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 17, 1998
The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543H J Showell, M J Conklyn, R Alpert, et al.
Pageof 6